Fennec Pharmaceuticals Inc. (OTCMKTS:FENCF) Files An 8-K Changes in Registrant’s Certifying Accountant
Item 4.01
| Changes in Registrants Certifying Accountant |
(a) The Audit Committee (the Committee) of the Board of Directors
of Fennec Pharmaceuticals Inc. (the Company) recently conducted a
competitive selection process to determine the Companys
independent registered public accounting firm for the fiscal year
ending December 31, 2017. This search began after Deloitte LLP
(Deloitte) advised the Company it would resign as of May 15,
2017. The Committee invited several independent public accounting
firms to participate in this process.
The reports of Deloitte on the Companys consolidated financial
statements for the fiscal years ended December 31, 2016 and 2015
did not contain an adverse opinion or disclaimer of opinion and
were not qualified or modified as to uncertainty, audit scope or
accounting principles. In connection with the audits of the
Company’s consolidated financial statements for the fiscal years
ended December 31, 2016 and 2015, and in the subsequent interim
period through May 15, 2017, there were no disagreements with
Deloitte on any matters of accounting principles or practices,
financial statement disclosure or auditing scope and procedures
which, if not resolved to the satisfaction of Deloitte, would
have caused Deloitte to make reference to the matter in their
report. There were no reportable events (as that term is
described in Item 304(a)(1)(v) of Regulation S-K of the
Securities Act of 1933, as amended) during the two fiscal years
ended December 31, 2016 and 2015, or in the subsequent period
through May 15, 2017.
The Company has provided a copy of the foregoing disclosures to
Deloitte and requested that Deloitte furnish it with a letter
addressed to the Securities and Exchange Commission stating
whether Deloitte agrees with the above statements. A copy of
Deloittes letter, dated May 17, 2017, is filed as Exhibit 16.1 to
this Form 8-K.
(b) The Committee approved the appointment of Haskell White LLP
as the Companys independent registered public accounting firm on
May 15, 2017, for the fiscal year ending December 31, 2017.
During the two most recent fiscal years and in the subsequent
interim period through May 15, 2017, the Company has not
consulted with Haskell White LLP with respect to the application
of accounting principles to a specified transaction, either
completed or proposed, or the type of audit opinion that would
have been rendered on the Companys consolidated financial
statements, or any other matters set forth in Item 304(a)(2)(i)
or (ii) of Regulation S-K.
| Item 9.01 | Financial Statements and Exhibits. |
| Exhibit No. | Description | |
| Exhibit 16.1 |
Letter from Deloitte LLP to the Securities and Exchange Commission dated May 17, 2017. |
About Fennec Pharmaceuticals Inc. (OTCMKTS:FENCF)
Fennec Pharmaceuticals Inc., formerly Adherex Technologies Inc., is a biopharmaceutical company focused on cancer therapeutics. The Company’s lead product candidate in the clinical stage of development includes Sodium Thiosulfate (STS), which has completed patient enrollment of over two Phase III clinical trials for the prevention of cisplatin induced hearing loss, or ototoxicity in children. STS has been studied by cooperative groups in over two Phase III clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. The Children’s Oncology Group (COG) ACCL0431 protocol enrolled 20% childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors. Fennec Pharmaceuticals Inc. (OTCMKTS:FENCF) Recent Trading Information
Fennec Pharmaceuticals Inc. (OTCMKTS:FENCF) closed its last trading session up +0.04 at 3.68 with 4,125 shares trading hands.